OBJECTIVE: Arginase stimulates the proliferation of cultured vascular smooth muscle cells (VSMCs); however, the influence of arginase on VSMC growth in vivo is not known. This study investigated the impact of arginase on cell cycle progression and neointima formation after experimental arterial injury. METHODS AND RESULTS: Balloon injury of rat carotid arteries resulted in a sustained increase in arginase activity in the vessel wall and the induction of arginase I protein in both the media and neointima of injured vessels. Furthermore, local perivascular application of the potent and selective arginase inhibitors S-(2-boronoethyl)-L-cysteine (BEC) or N(G)-hydroxy-nor-L-arginine (L-OHNA) immediately after injury markedly attenuated medial and neointimal DNA synthesis and neointima formation. Substantial arginase I protein and arginase activity was also detected in rat cultured aortic VSMCs. Moreover, treatment of VSMCs with BEC or L-OHNA, or knockdown of arginase I protein, arrested cells in the G(0)/G(1) phase of the cell cycle and induced the expression of the cyclin-dependent protein kinase inhibitor, p21. CONCLUSIONS: This study demonstrates that arginase is essential for VSMCs to enter the cell cycle and that arginase I contributes to the remodeling response after arterial injury. Arginase I represents a potentially new therapeutic target for the treatment of vasculoproliferative disorders.
OBJECTIVE: Arginase stimulates the proliferation of cultured vascular smooth muscle cells (VSMCs); however, the influence of arginase on VSMC growth in vivo is not known. This study investigated the impact of arginase on cell cycle progression and neointima formation after experimental arterial injury. METHODS AND RESULTS:Balloon injury of rat carotid arteries resulted in a sustained increase in arginase activity in the vessel wall and the induction of arginase I protein in both the media and neointima of injured vessels. Furthermore, local perivascular application of the potent and selective arginase inhibitors S-(2-boronoethyl)-L-cysteine (BEC) or N(G)-hydroxy-nor-L-arginine (L-OHNA) immediately after injury markedly attenuated medial and neointimal DNA synthesis and neointima formation. Substantial arginase I protein and arginase activity was also detected in rat cultured aortic VSMCs. Moreover, treatment of VSMCs with BEC or L-OHNA, or knockdown of arginase I protein, arrested cells in the G(0)/G(1) phase of the cell cycle and induced the expression of the cyclin-dependent protein kinase inhibitor, p21. CONCLUSIONS: This study demonstrates that arginase is essential for VSMCs to enter the cell cycle and that arginase I contributes to the remodeling response after arterial injury. Arginase I represents a potentially new therapeutic target for the treatment of vasculoproliferative disorders.
Authors: D A Tulis; W Durante; K J Peyton; G B Chapman; A J Evans; A I Schafer Journal: Biochem Biophys Res Commun Date: 2000-12-20 Impact factor: 3.575
Authors: H Li; C J Meininger; J R Hawker; T E Haynes; D Kepka-Lenhart; S K Mistry; S M Morris; G Wu Journal: Am J Physiol Endocrinol Metab Date: 2001-01 Impact factor: 4.310
Authors: Thomas Schachner; Yping Zou; Alexander Oberhuber; Alexandar Tzankov; Thomas Mairinger; Günther Laufer; Johannes O Bonatti Journal: Ann Thorac Surg Date: 2004-05 Impact factor: 4.330
Authors: Surabhi Chandra; David J R Fulton; Ruth B Caldwell; R William Caldwell; Haroldo A Toque Journal: Eur J Pharmacol Date: 2018-11-28 Impact factor: 4.432
Authors: Xiao-ming Liu; Kelly J Peyton; Ahmad R Shebib; Hong Wang; Ronald J Korthuis; William Durante Journal: Am J Physiol Heart Circ Physiol Date: 2010-10-29 Impact factor: 4.733
Authors: Kelly J Peyton; Yajie Yu; Benjamin Yates; Ahmad R Shebib; Xiao-ming Liu; Hong Wang; William Durante Journal: J Pharmacol Exp Ther Date: 2011-05-12 Impact factor: 4.030